BrainsWay Ltd. (BWAY)

NASDAQ: BWAY · IEX Real-Time Price · USD
6.13
-0.08 (-1.29%)
At close: Jun 14, 2024, 4:00 PM
6.37
+0.24 (3.92%)
After-hours: Jun 14, 2024, 4:59 PM EDT
-1.29%
Market Cap 102.15M
Revenue (ttm) 34.26M
Net Income (ttm) -1.66M
Shares Out 16.66M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,635
Open 6.20
Previous Close 6.21
Day's Range 6.13 - 6.36
52-Week Range 2.01 - 7.62
Beta 0.32
Analysts Buy
Price Target 13.00 (+112.07%)
Earnings Date Aug 7, 2024

About BWAY

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospi... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Apr 17, 2019
Employees 134
Stock Exchange NASDAQ
Ticker Symbol BWAY
Full Company Profile

Financial Performance

In 2023, BrainsWay's revenue was $31.79 million, an increase of 16.96% compared to the previous year's $27.18 million. Losses were -$4.20 million, -68.56% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for BWAY stock is "Buy." The 12-month stock price forecast is $13.0, which is an increase of 112.07% from the latest price.

Price Target
$13.0
(112.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™ Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™

4 days ago - GlobeNewsWire

BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression

Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Treatment in Patients Between the Ages of 68 and 86 Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Tr...

11 days ago - GlobeNewsWire

BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights

Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for...

5 weeks ago - GlobeNewsWire

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

BURLINGTON, Mass. and JERUSALEM, April 24, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatm...

7 weeks ago - GlobeNewsWire

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms

2 months ago - GlobeNewsWire

BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Katie's Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families Katie's Way Provides Lifesaving Mental Health Treatment Nationally with ...

3 months ago - GlobeNewsWire

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Generated Record Revenues with Robust 50% Year-over-Year Revenue Growth in Q4 2023;  Generated Positive Quarterly Net Income

3 months ago - GlobeNewsWire

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

4 months ago - GlobeNewsWire

BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology

BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

5 months ago - GlobeNewsWire

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

6 months ago - GlobeNewsWire

BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea

BURLINGTON, Mass. and JERUSALEM, Dec. 07, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

6 months ago - GlobeNewsWire

Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives

BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...

7 months ago - GlobeNewsWire

BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights

Generated Robust 61% Year-over-Year Revenue Growth in Q3 2023 Nearing Breakeven Operating Income, Achieved Positive Adjusted EBITDA, with Cash Flow from Operations Exceeding $1 Million Conference Call...

7 months ago - GlobeNewsWire

BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression

Peer-reviewed Results Suggest Accelerated Deep TMS Outcomes Comparable to Standard Treatment Protocols Peer-reviewed Results Suggest Accelerated Deep TMS Outcomes Comparable to Standard Treatment Prot...

8 months ago - GlobeNewsWire

BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie's Way Plus

Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems

9 months ago - GlobeNewsWire

BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S.

BURLINGTON, Mass. and JERUSALEM, Sept.

10 months ago - GlobeNewsWire

BrainsWay Further Expands Access to Deep TMS™ in Asia Pacific Region

Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS™ in Taiwan Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS™ in Taiwan

10 months ago - GlobeNewsWire

BrainsWay Reports Second Quarter 2023 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain ...

11 months ago - GlobeNewsWire

BrainsWay Announces Publication of Three New Deep TMS Research Publications

New Articles Enhance Understanding of Deep TMS Safety Profile and Survey Addiction Research New Articles Enhance Understanding of Deep TMS Safety Profile and Survey Addiction Research

11 months ago - GlobeNewsWire

BrainsWay Accelerates International Expansion in India

Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™ Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™

1 year ago - GlobeNewsWire

BrainsWay Announces Significant Expansion in Western and Central U.S.

30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS Network 30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS Network

1 year ago - GlobeNewsWire

BrainsWay Announces Appointment of Ido Marom as CFO

BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...

1 year ago - GlobeNewsWire

BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain d...

1 year ago - GlobeNewsWire

BrainsWay Launches Investigator Initiated Study (IIS) Program

Application Period Open for Data Collaboration and Equipment Loan Initiatives Application Period Open for Data Collaboration and Equipment Loan Initiatives

1 year ago - GlobeNewsWire

BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023

BURLINGTON, Mass. and JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...

1 year ago - GlobeNewsWire